Doctor Y Goldstein
Overview
Explore the profile of Doctor Y Goldstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nhan N, Liu T, Almushajrah A, Mozumder A, Narlieva M, Szymczak W, et al.
Microbiol Spectr
. 2025 Feb;
:e0211424.
PMID: 39950809
Importance: is a multidrug-resistant yeast responsible for severe infections with high mortality rates. Rapid and accurate detection is critical for preventing the spread of this pathogen in healthcare settings. This...
2.
Krishnamurthy K, Chai J, Liu X, Elsayad M, Goldstein D
Pathol Res Pract
. 2024 Sep;
263:155577.
PMID: 39265501
Majority of the lung adenocarcinomas show a mixture of different histological patterns. The possibility of histologically heterogeneous areas of the adenocarcinoma showing genetic heterogeneity and harboring different driver mutations, with...
3.
Krishnamurthy K, Edema U, Ustun B, Villanueva-Siles E, Koehler S, Naeem R, et al.
J Surg Case Rep
. 2023 Oct;
2023(10):rjad549.
PMID: 37846420
PIK3CA-related overgrowth spectrum (PROS) is a heterogeneous group of diseases, with varied clinical presentations ranging from isolated segmental overgrowths to megalencephaly and vascular malformations, all resulting from post-zygotic activating mutations...
4.
Pierce C, Sy S, Galen B, Goldstein D, Orner E, Keller M, et al.
JCI Insight
. 2021 Apr;
6(9).
PMID: 33822777
BACKGROUNDCoronavirus disease 2019 (COVID-19) is more benign in children compared with adults for unknown reasons. This contrasts with other respiratory viruses where disease manifestations are often more severe in children....
5.
Pierce C, Sy S, Galen B, Goldstein D, Orner E, Keller M, et al.
medRxiv
. 2021 Feb;
PMID: 33594377
COVID-19 is more benign in children compared to adults for unknown reasons. This contrasts with viruses such as influenza where disease manifestations are often more severe in children1. We hypothesized...
6.
Yoon H, Bartash R, Gendlina I, Rivera J, Nakouzi A, Bortz 3rd R, et al.
JCI Insight
. 2021 Jan;
6(4).
PMID: 33476300
Convalescent plasma with severe acute respiratory disease coronavirus 2 (SARS-CoV-2) antibodies (CCP) may hold promise as a treatment for coronavirus disease 2019 (COVID-19). We compared the mortality and clinical outcome...
7.
Yoon H, Bartash R, Gendlina I, Rivera J, Nakouzi A, Bortz 3rd R, et al.
medRxiv
. 2020 Dec;
PMID: 33300012
Convalescent plasma with severe acute respiratory disease coronavirus 2 (SARS-CoV-2) antibodies (CCP) may hold promise as treatment for Coronavirus Disease 2019 (COVID-19). We compared the mortality and clinical outcome of...
8.
Torabi J, Rocca J, Ajaimy M, Melvin J, Campbell A, Akalin E, et al.
Transpl Infect Dis
. 2020 Aug;
23(1):e13449.
PMID: 32810315
Introduction: The advent of direct-acting antivirals (DAAs) has created an avenue for transplantation of hepatitis C virus (HCV)-infected donors into uninfected recipients (D+/R-). The donor transmission of HCV is then...
9.
Graham J, Torabi J, Ajaimy M, Akalin E, Liriano L, Azzi Y, et al.
Clin Transplant
. 2020 Feb;
34(4):e13833.
PMID: 32072689
The advent of direct-acting antivirals (DAAs) has provided the impetus to transplant kidneys from hepatitis C virus-positive donors into uninfected recipients (D+/R-). Thirty D+/R- patients received DAA treatment. Sustained virologic...
10.
Patel S, Madan S, Saeed O, Sims D, Shin J, Nucci C, et al.
J Heart Lung Transplant
. 2018 Aug;
37(10):1254-1260.
PMID: 30126825
Background: Hepatitis C (HCV) donors are rarely used for cardiac transplantation due to historically poor outcomes. In 2015, nucleic acid testing (NAT) for viral load was added to the routine...